Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861340 · ClinicalTrials.gov registry record · Early Phase 1
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
A Early Phase 1 study of Myeloma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01861340: Completed Early Phase 1 study of Myeloma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT01861340 is a Early Phase 1 study of Myeloma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 20 participants, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01861340, a Early Phase 1 study of Myeloma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Conditions Studied
Interventions
- DRUG Lenalidomide, Dexamethasone, and MEDI-551
Study Locations (1)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
What the finished NCT01861340 record still lists
NCT01861340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide, Dexamethasone, and MEDI-551 is the first listed.
NCT01861340 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01861340 about?
NCT01861340 is a clinical study titled "Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma". This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
What is the current status of trial NCT01861340?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2014-05. Estimated completion is 2016-07.
What conditions does trial NCT01861340 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT01861340?
The interventions under investigation include: Lenalidomide, Dexamethasone, and MEDI-551 (DRUG).
Who is sponsoring clinical trial NCT01861340?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01861340 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01861340's enrollment target sits among peer trials
20 26th of 29 higher than 3 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
ACTIVE NOT RECRUITING · Early Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 1
-
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RECRUITING · Phase 2
-
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia